What is Blood Plasma Products Market?
Blood plasma is a liquid component that carries cells and proteins throughout the body. It is mostly water and contain dissolve proteins, glucose, oxygen, hormones, electrolytes, etc. It protect the body from infection and other blood disorder and also balance the electrolyte concentration. Blood plasma products used in several therapeutic treatments. The blood plasma products are used in hospitals, clinics and by research firms. Immunoglobulins is a component that is present in blood plasma which is further segmented into intravenous, subcutaneous and normal immunoglobulins.
The market study is being classified, by Application (Immunology, Oncology, Pulmonology, Rheumatology, Transplant, Neurology and Hematology) and major geographies with country level break-up.
ADMA Biologics, Inc. (United States), Cerus Corporation (United States), China Biologic Products, Inc. (China), CSL Limited (Australia), Biotest (Germany), Intas Pharmaceuticals Limited (India), Kedrion (Italy), LFB S.A. (France), Octapharma AG (Switzerland) and PrIME Biologics Pte Ltd. (Singapore) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Shanghai RAAS Blood Products Co., Ltd (China) and Sanquin (Netherlands).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Blood Plasma Products market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Blood Plasma Products market by Type, Application and Region.
On the basis of geography, the market of Blood Plasma Products has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increase in Prevalence of Life-Threatening Disorders like Hemophilia
- Increasing Usage in Plasma-Derived Medical Products
Market Trend
- Increasing Awareness about Blood and Plasma Donation
- Introduction of New and Specialized Products
Restraints
- High Cost of Plasma Derivative-Based Therapy
Opportunities
- High Potential in Untapped Markets in the Emerging Economies
Challenges
- Post-Operative Risks Associated with Plasma Replacement Therapy
April 9, 2019: Biotest AG opens ninth plasma collection centre in Hungary- 21 plasma collection centres in Europe to ensure long-term plasma supply Dreieich.
USFDA and Centre for biologics evaluation and research (CBER): The Clinical Laboratory Improvement Amendments (CLIA) of 1988 21 CFR Code of Federal Regulations, 606: cGMP for blood and blood components. and Regulation in Europe: Blood and blood products regulation is described in blood directive 2002/98/EC of European Parliament and council on setting “standards of safety and quality for the collection, processing, testing, storage and distribution of human blood and blood components “and directive 2005/62/EC which specified “community standard and specification relating to a quality system for blood establishment”.
Key Target Audience
Manufacturers of Blood Plasma Product, Suppliers of Blood Plasma Product, Wholesalers, Distributers and Retailers of Blood Plasma Product, Healthcare Industry, Research Firms and Governmental Bodies